Kiniksa Pharmaceuticals International, plc
KNSA Nasdaq Pharmaceutical Preparations Financials FY2017–FY2025
Revenue
Total sales reported in the income statement.
$678M
60.1%
vs prior year
Operating margin
Operating income as a share of revenue.
11.4%
22.2 pts
Net income
Profit after all expenses, interest and tax.
$59.0M
Free cash flow
Cash from operations minus capital spending.
$136M
436.8%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On $0.91 EPS (TTM)
What Kiniksa Pharmaceuticals International, plc does
No business description yet.
- Legal name
- Kiniksa Pharmaceuticals International, plc
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Accession · CIK
- 0001104659-26-019168
0001730430
Revenue and margins
Kiniksa Pharmaceuticals International, plc had $678M of revenue in fiscal 2025, up 60.1% on the year before.
FY17
Revenue —
FY18
Revenue —
FY19
Revenue —
FY20
Revenue —
FY21
Revenue $38.5M
FY22
Revenue $220M
FY23
Revenue $270M
FY24
Revenue $423M
FY25
Revenue $678M
Q2 '23
Revenue $71.5M
Q3 '23
Revenue $67.0M
Q4 '23
Revenue $83.4M
Q1 '24
Revenue $79.9M
Q2 '24
Revenue $109M
Q3 '24
Revenue $112M
Q4 '24
Revenue $123M
Q1 '25
Revenue $138M
Q2 '25
Revenue $157M
Q3 '25
Revenue $181M
Q4 '25
Revenue $202M
Q1 '26
Revenue $214M
FY17
Gross —
Operating —
Net —
FCF —
FY18
Gross —
Operating —
Net —
FCF —
FY19
Gross —
Operating —
Net —
FCF —
FY20
Gross —
Operating —
Net —
FCF —
FY21
Gross 76.4%
Operating −406.4%
Net −409.7%
FCF −328.7%
FY22
Gross 89.6%
Operating 4.4%
Net 83.3%
FCF 2.6%
FY23
Gross 87.6%
Operating −9.3%
Net 5.2%
FCF 4.9%
FY24
Gross 85.6%
Operating −10.8%
Net −10.2%
FCF 6.0%
FY25
Gross 88.5%
Operating 11.4%
Net 8.7%
FCF 20.1%
Gross
Operating
Net
FCF
Q2 '23
Gross 89.2%
Operating −4.4%
Net 20.9%
FCF −5.3%
Q3 '23
Gross 86.4%
Operating −16.3%
Net −20.7%
FCF 25.3%
Q4 '23
Gross 88.5%
Operating 0.1%
Net 30.3%
FCF 5.1%
Q1 '24
Gross 86.7%
Operating −20.7%
Net −22.2%
FCF 4.9%
Q2 '24
Gross 88.7%
Operating −0.1%
Net −3.6%
FCF 4.8%
Q3 '24
Gross 82.1%
Operating −8.6%
Net −11.3%
FCF −2.0%
Q4 '24
Gross 85.4%
Operating −15.7%
Net −7.3%
FCF 15.2%
Q1 '25
Gross 87.0%
Operating 9.6%
Net 6.2%
FCF 16.1%
Q2 '25
Gross 88.1%
Operating 12.9%
Net 11.4%
FCF 17.8%
Q3 '25
Gross 88.8%
Operating 13.3%
Net 10.2%
FCF 18.3%
Q4 '25
Gross 89.6%
Operating 9.8%
Net 7.0%
FCF 26.4%
Q1 '26
Gross 90.3%
Operating 13.7%
Net 10.5%
FCF 23.4%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY17
Net income −$64.9M
FY18
Net income −$103M
FY19
Net income −$162M
FY20
Net income −$161M
FY21
Net income −$158M
FY22
Net income $183M
FY23
Net income $14.1M
FY24
Net income −$43.2M
FY25
Net income $59.0M
Q2 '23
Net income $15.0M
Q3 '23
Net income −$13.9M
Q4 '23
Net income $25.2M
Q1 '24
Net income −$17.7M
Q2 '24
Net income −$3.9M
Q3 '24
Net income −$12.7M
Q4 '24
Net income −$8.9M
Q1 '25
Net income $8.5M
Q2 '25
Net income $17.8M
Q3 '25
Net income $18.4M
Q4 '25
Net income $14.2M
Q1 '26
Net income $22.6M
FY17
Diluted EPS −$35.85
FY18
Diluted EPS −$3.49
FY19
Diluted EPS −$2.99
FY20
Diluted EPS −$2.61
FY21
Diluted EPS −$2.30
FY22
Diluted EPS $2.60
FY23
Diluted EPS $0.20
FY24
Diluted EPS −$0.60
FY25
Diluted EPS $0.75
Q2 '23
Diluted EPS $0.21
Q3 '23
Diluted EPS −$0.20
Q4 '23
Diluted EPS $0.37
Q1 '24
Diluted EPS −$0.25
Q2 '24
Diluted EPS −$0.06
Q3 '24
Diluted EPS −$0.18
Q4 '24
Diluted EPS −$0.11
Q1 '25
Diluted EPS $0.11
Q2 '25
Diluted EPS $0.23
Q3 '25
Diluted EPS $0.23
Q4 '25
Diluted EPS $0.18
Q1 '26
Diluted EPS $0.27
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY17
Return on capital —
Return on equity —
Return on assets −136.6%
FY18
Return on capital —
Return on equity −108.9%
Return on assets −55.9%
FY19
Return on capital —
Return on equity −64.1%
Return on assets −56.2%
FY20
Return on capital —
Return on equity −60.1%
Return on assets −53.4%
FY21
Return on capital —
Return on equity −63.6%
Return on assets −54.2%
FY22
Return on capital —
Return on equity 63.1%
Return on assets 53.0%
FY23
Return on capital —
Return on equity 3.4%
Return on assets 2.9%
FY24
Return on capital —
Return on equity −9.8%
Return on assets −7.8%
FY25
Return on capital —
Return on equity 11.7%
Return on assets 8.8%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $136M in fiscal 2025, 20.1% of revenue. Cash from operations minus capital spending.
FY17
Free cash flow −$50.3M
FY18
Free cash flow −$86.3M
FY19
Free cash flow −$162M
FY20
Free cash flow −$137M
FY21
Free cash flow −$127M
FY22
Free cash flow $5.7M
FY23
Free cash flow $13.2M
FY24
Free cash flow $25.4M
FY25
Free cash flow $136M
Q2 '23
Free cash flow −$3.8M
Q3 '23
Free cash flow $17.0M
Q4 '23
Free cash flow $4.3M
Q1 '24
Free cash flow $3.9M
Q2 '24
Free cash flow $5.2M
Q3 '24
Free cash flow −$2.2M
Q4 '24
Free cash flow $18.6M
Q1 '25
Free cash flow $22.2M
Q2 '25
Free cash flow $27.9M
Q3 '25
Free cash flow $33.0M
Q4 '25
Free cash flow $53.3M
Q1 '26
Free cash flow $50.0M
FY17
Cash from operations −$50.2M
Capital spending $0.1M
FY18
Cash from operations −$81.0M
Capital spending $5.3M
FY19
Cash from operations −$158M
Capital spending $3.2M
FY20
Cash from operations −$137M
Capital spending $0.3M
FY21
Cash from operations −$126M
Capital spending $0.4M
FY22
Cash from operations $5.8M
Capital spending $0.1M
FY23
Cash from operations $13.3M
Capital spending $0.1M
FY24
Cash from operations $25.7M
Capital spending $0.3M
FY25
Cash from operations $138M
Capital spending $1.6M
Cash from operations
Capital spending
Q2 '23
Cash from operations −$3.7M
Capital spending $0.0M
Q3 '23
Cash from operations $17.0M
Capital spending $0.0M
Q4 '23
Cash from operations $4.3M
Capital spending $0.1M
Q1 '24
Cash from operations $4.0M
Capital spending $0.1M
Q2 '24
Cash from operations $5.2M
Capital spending $0.0M
Q3 '24
Cash from operations −$2.2M
Capital spending $0.0M
Q4 '24
Cash from operations $18.8M
Capital spending $0.2M
Q1 '25
Cash from operations $22.3M
Capital spending $0.1M
Q2 '25
Cash from operations $28.1M
Capital spending $0.2M
Q3 '25
Cash from operations $33.7M
Capital spending $0.7M
Q4 '25
Cash from operations $53.9M
Capital spending $0.6M
Q1 '26
Cash from operations $50.2M
Capital spending $0.2M
Cash from operations
Capital spending
Dividends, buybacks and share count
Kiniksa Pharmaceuticals International, plc returned — to shareholders in fiscal 2025. The diluted share count rose 10.6%.
FY17
Dividends $0.0M
Buybacks —
FY18
Dividends $0.0M
Buybacks —
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY17
Diluted shares 0.00B
FY18
Diluted shares 0.03B
FY19
Diluted shares 0.05B
FY20
Diluted shares 0.06B
FY21
Diluted shares 0.07B
FY22
Diluted shares 0.07B
FY23
Diluted shares 0.07B
FY24
Diluted shares 0.07B
FY25
Diluted shares 0.08B
Balance sheet
Cash, debt and the ratios that show how comfortably Kiniksa Pharmaceuticals International, plc can carry it.
FY17
Cash $45.6M
Debt —
FY18
Cash $307M
Debt —
FY19
Cash $233M
Debt —
FY20
Cash $323M
Debt —
FY21
Cash $182M
Debt —
FY22
Cash $191M
Debt —
FY23
Cash $206M
Debt —
FY24
Cash $244M
Debt —
FY25
Cash $414M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $182M | $191M | $206M | $244M | $414M |
| Current ratio | 4.4x | 5.2x | 4.3x | 3.3x | 3.8x |
| Quick ratio | 4.3x | 4.7x | 3.9x | 3.0x | 3.4x |
| Total assets | $233M | $460M | $526M | $581M | $764M |
| Total liabilities | $47.8M | $63.5M | $87.5M | $142M | $196M |
| Shareholders' equity | $185M | $396M | $439M | $438M | $568M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ | ✓ | ✕ | ✓ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✓ | ✕ | ✓ | ✕ | ✓ | ✕ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — | — | — | — | — |
| Current ratio rose | — | ✓ | ✓ | ✓ | ✕ | ✓ | ✕ | ✕ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ | ✕ |
| Gross margin rose | — | — | — | — | — | ✓ | ✕ | ✕ | ✓ |
| Revenue rose relative to assets | — | — | — | — | — | ✓ | ✓ | ✓ | ✓ |
| F-score | — / 3 | — / 6 | — / 6 | — / 6 | — / 6 | 6 / 8 | 3 / 8 | 4 / 8 | 7 / 8 |
| Accruals ratio | −30.9% | −12.0% | −1.2% | −8.2% | −10.9% | 51.3% | 0.2% | −12.4% | −11.8% |
| Altman Z'' | −16.81 | 8.17 | 4.59 | 6.53 | −5.64 | 6.00 | 4.64 | 2.40 | 5.08 |
9 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | $38.5M | $220M | $270M | $423M | $678M |
| Gross profit | — | — | — | — | $29.4M | $197M | $237M | $362M | $600M |
| Research and development | $56.4M | $86.6M | $135M | $112M | $99.3M | $65.5M | $76.1M | $112M | $96.9M |
| Operating income | −$65.4M | −$108M | −$170M | −$157M | −$157M | $9.8M | −$25.2M | −$45.6M | $77.2M |
| Pretax income | −$64.9M | −$103M | −$164M | −$156M | −$157M | $11.0M | −$16.7M | −$36.2M | $88.9M |
| Income tax | $0.0M | −$0.2M | −$2.0M | $5.2M | $1.4M | −$172M | −$30.7M | $7.0M | $29.9M |
| Net income | −$64.9M | −$103M | −$162M | −$161M | −$158M | $183M | $14.1M | −$43.2M | $59.0M |
| Diluted EPS | −$35.85 | −$3.49 | −$2.99 | −$2.61 | −$2.30 | $2.60 | $0.20 | −$0.60 | $0.75 |
| Diluted shares | 0.00B | 0.03B | 0.05B | 0.06B | 0.07B | 0.07B | 0.07B | 0.07B | 0.08B |
| Cash flow | |||||||||
| Cash from operations | −$50.2M | −$81.0M | −$158M | −$137M | −$126M | $5.8M | $13.3M | $25.7M | $138M |
| Capital expenditure | $0.1M | $5.3M | $3.2M | $0.3M | $0.4M | $0.1M | $0.1M | $0.3M | $1.6M |
| Free cash flow | −$50.3M | −$86.3M | −$162M | −$137M | −$127M | $5.7M | $13.2M | $25.4M | $136M |
| Depreciation and amortization | $0.0M | $0.3M | $2.1M | $2.4M | $2.4M | $2.4M | $2.3M | $1.7M | $1.6M |
| Stock-based compensation | $0.9M | $5.7M | $15.1M | $20.9M | $25.2M | $25.1M | $27.1M | $30.7M | $37.0M |
| Dividends paid | $0.0M | $0.0M | — | — | — | — | — | — | — |
| Dividends and buybacks | $0.0M | $0.0M | — | — | — | — | — | — | — |
| Balance sheet | |||||||||
| Cash and short-term investments | $45.6M | $307M | $233M | $323M | $182M | $191M | $206M | $244M | $414M |
| Current assets | $47.1M | $314M | $242M | $333M | $196M | $243M | $276M | $332M | $527M |
| Current liabilities | $17.4M | $42.6M | $27.8M | $31.8M | $44.8M | $47.1M | $63.7M | $101M | $139M |
| Inventory | — | — | — | $0.0M | $3.7M | $21.6M | $31.1M | $26.4M | $54.9M |
| Property and equipment, net | $0.1M | $6.4M | $6.4M | $4.1M | $2.8M | $1.7M | $0.7M | $0.7M | $1.9M |
| Intangible assets | — | — | — | $0.0M | $19.3M | $18.3M | $17.3M | $16.3M | $15.3M |
| Total assets | $47.5M | $322M | $255M | $349M | $233M | $460M | $526M | $581M | $764M |
| Total liabilities | $17.4M | $42.7M | $29.1M | $37.5M | $47.8M | $63.5M | $87.5M | $142M | $196M |
| Shareholders' equity | −$89.7M | $279M | $225M | $312M | $185M | $396M | $439M | $438M | $568M |
| Margins | |||||||||
| Gross margin | — | — | — | — | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating margin | — | — | — | — | −406.4% | 4.4% | −9.3% | −10.8% | 11.4% |
| EBITDA margin | — | — | — | — | −400.3% | 5.5% | −8.5% | −10.4% | 11.6% |
| Net margin | — | — | — | — | −409.7% | 83.3% | 5.2% | −10.2% | 8.7% |
| FCF margin | — | — | — | — | −328.7% | 2.6% | 4.9% | 6.0% | 20.1% |
| Returns | |||||||||
| Return on capital employed | −217.6% | −38.7% | −75.0% | −49.5% | −83.3% | 2.4% | −5.4% | −9.5% | 12.4% |
| Return on equity | — | −108.9% | −64.1% | −60.1% | −63.6% | 63.1% | 3.4% | −9.8% | 11.7% |
| Return on assets | −136.6% | −55.9% | −56.2% | −53.4% | −54.2% | 53.0% | 2.9% | −7.8% | 8.8% |
| Return on tangible equity | — | −37.0% | −71.8% | −51.7% | −95.3% | 48.5% | 3.3% | −10.2% | 10.7% |
| Growth | |||||||||
| Revenue growth | — | — | — | — | — | 471.2% | 22.7% | 56.6% | 60.1% |
| Net income growth | — | — | — | — | — | — | −92.3% | −406.7% | — |
| EPS growth | — | — | — | — | — | — | −92.3% | −400.0% | — |
| FCF growth | — | — | — | — | — | — | 131.0% | 92.9% | 436.8% |
| Share count change | — | 1,532.6% | 82.9% | 14.4% | 10.9% | 2.7% | 2.1% | −0.7% | 10.6% |
| Financial health | |||||||||
| Current ratio | 2.7x | 7.4x | 8.7x | 10.5x | 4.4x | 5.2x | 4.3x | 3.3x | 3.8x |
| Quick ratio | 2.7x | 7.4x | 8.7x | 10.5x | 4.3x | 4.7x | 3.9x | 3.0x | 3.4x |
| Capital allocation | |||||||||
| Capex / revenue | — | — | — | — | 1.1% | 0.0% | 0.0% | 0.1% | 0.2% |
| Stock comp / revenue | — | — | — | — | 65.3% | 11.4% | 10.0% | 7.3% | 5.5% |
| Quality scores | |||||||||
| Piotroski F-score | — | — | — | — | — | 6.0 | 3.0 | 4.0 | 7.0 |
| Altman Z'' | −16.8 | 8.2 | 4.6 | 6.5 | −5.6 | 6.0 | 4.6 | 2.4 | 5.1 |
| Accruals ratio | −30.9% | −12.0% | −1.2% | −8.2% | −10.9% | 51.3% | 0.2% | −12.4% | −11.8% |
Source: SEC EDGAR XBRL filings (CIK 0001730430). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.